16.40
0.24 (1.49%)
| Previous Close | 16.16 |
| Open | 16.27 |
| Volume | 228,165 |
| Avg. Volume (3M) | 503,606 |
| Market Cap | 1,242,060,288 |
| Price / Sales | 10.37 |
| Price / Book | 3.83 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -121.73% |
| Operating Margin (TTM) | -94.48% |
| Diluted EPS (TTM) | -1.50 |
| Quarterly Revenue Growth (YOY) | 170.30% |
| Total Debt/Equity (MRQ) | 5.68% |
| Current Ratio (MRQ) | 4.71 |
| Operating Cash Flow (TTM) | -75.78 M |
| Levered Free Cash Flow (TTM) | -21.20 M |
| Return on Assets (TTM) | -13.89% |
| Return on Equity (TTM) | -29.80% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Zymeworks Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | 4.0 |
| Average | 0.75 |
|
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.15% |
| % Held by Institutions | 102.76% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (B. Riley Securities, 82.93%) | Buy |
| Median | 24.50 (49.39%) | |
| Low | 22.00 (Citigroup, 34.15%) | Buy |
| Average | 25.25 (53.96%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 16.96 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 16 Oct 2025 | 23.00 (40.24%) | Buy | 19.12 |
| HC Wainwright & Co. | 14 Oct 2025 | 26.00 (58.54%) | Buy | 18.23 |
| B. Riley Securities | 10 Oct 2025 | 30.00 (82.93%) | Buy | 18.06 |
| Citigroup | 11 Aug 2025 | 22.00 (34.15%) | Buy | 12.44 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |